In direct compression campaigns for oral solid dosage forms containing the final morpholine-triazolinone NK1 antagonist derived from this chiral intermediate, the hydrochloride salt itself is not compressed as the active entity; instead, the stereochemically defined morpholine intermediate is converted through N-alkylation or heterocycle condensation to the neutral final API, after which the drug substance is blended with microcrystalline cellulose, lactose monohydrate, crospovidone, and sodium stearyl fumarate. Tablet robustness is governed by the persistence of the (2S,3R)-morpholine diastereomer, because an enantiomeric excess below 99.0% in the intermediate can alter crystal habit, compressibility, and dissolution of the finished tablet. During scale-up on a rotary tablet press fitted with B-tooling and 10.5 mm round punches, compaction force is maintained between 60 MPa and 180 MPa to produce tablet hardness of 60–120 N on a Schleuniger hardness tester. Disintegration time is measured according to USP <701> at 37 ± 0.5 °C; batches showing disintegration times longer than 15 min are rejected because the final API is poorly soluble under fasted gastric pH conditions and requires rapid tablet breakup before dissolution can proceed. Content uniformity is assessed by USP <905>, with an acceptance value not exceeding 15.0 for ten units. Dissolution testing uses USP <711> Apparatus II at 75 rpm in a validated surfactant-enriched acidic medium; early development batches in which the intermediate contained more than 0.5% total related substances showed a decrease of Q value at 30 min of up to 8% when compared with high-purity intermediate batches. Near-infrared blend homogeneity monitoring is correlated to HPLC chiral purity data; the root-mean-square error of prediction is typically below 0.5% w/w for a low-dose formulation containing 4–8% w/w of final API. Relative humidity above 60% requires pre-drying of the final blend because the neutral API derived from this hydrophobic intermediate exhibits electrostatic agglomeration during low-shear mixing. Direct compression is not recommended when the final API concentration exceeds 20% w/w, because the poor compaction properties of the crystalline drug substance dominate and tablet tensile strength falls below 0.8 MPa; this operational boundary has been observed across multiple lab and pilot campaigns and motivates the use of granulation for higher-dose strengths. The hydrochloride salt itself should be stored in a dry environment below 30 °C and desiccated to prevent moisture-induced hydrolysis of the morpholine ether, but it is not directly blended with basic excipients such as sodium bicarbonate or meglumine because salt disproportionation can generate free base domains and cause powder flow variability.

Why Does Low-Dose Capsule Filling Require Free-Base Conversion Before Encapsulation?

Low-dose capsule filling of the neutral NK1 antagonist synthesised from the titled hydrochloride salt must account for the basicity of the morpholine nitrogen and the salt-to-free-base conversion step that precedes final API isolation. On a production dosator encapsulator with tamping-pin stations running at 60,000–120,000 capsules/hour, powder blends with a Carr index between 15% and 30% provide acceptable weight uniformity; blends outside this range produce fill weight relative standard deviations above 2.0% and content uniformity failures under USP <905>. Because the final API derived from this intermediate is poorly water-soluble and is typically micronized to a D90 of 5–10 µm by air-jet milling, agglomerates larger than 250 µm must be removed by screening through a 30-mesh sieve before encapsulation. The capsule fill formulation usually contains pregelatinized starch, sodium lauryl sulfate, and colloidal silicon dioxide; the latter is added at 0.2–0.5% w/w to reduce triboelectric charging during high-speed capsule filling. Humidity control is critical: at relative humidity above 55%, the capsule shell becomes plasticized and the fill powder gains sufficient surface moisture to reduce flow through the dosator nozzle, generating weight drift of up to 3% across a 500,000-capsule batch. Analytical release includes chiral HPLC to confirm that the (2S,3R)-diastereomer content of the final API is not more than 0.5% relative to the (2R,3S)-morpholine configuration. Dissolution of filled capsules is tested according to USP <711> using Apparatus I at 100 rpm or Apparatus II at 75 rpm in a surfactant-enriched medium; the Q value at 45 min is typically not less than 75% for batches produced from intermediates with enantiomeric excess above 99.5%. Capsule filling is not recommended for the unconverted hydrochloride salt because the salt is hygroscopic and produces variable fill weight on high-speed machinery; therefore free-base conversion and final API crystallization are fixed as prerequisite unit operations. Residual solvent levels from the intermediate synthesis are tested before capsule release; dichloromethane is controlled to not more than 600 ppm and methanol to not more than 3000 ppm under ICH Q3C Class 2 limits for oral products.

High-Shear Granulation Equipment and Binder Viscosity Constraints

Wet granulation of the final API derived from this chiral intermediate is selected when direct compression cannot meet content uniformity requirements for low-dose tablet or capsule products, particularly when the final API is present at less than 10% w/w of the core. Granulation is performed in a 65 L high-shear mixer bowl with an impeller tip speed of 4–8 m/s, a chopper speed of 1500–3000 rpm, and a wet massing time of 120–240 s. A binder solution of povidone K30 at 6% w/w in purified water is added over 2–4 min to a total liquid amount of 15–20% w/w of dry powder mass; the grade selection is binding because a 2% aqueous solution of povidone K30 has a viscosity of 2.4–4.0 mPa·s, whereas higher-viscosity binders extend disintegration beyond 15 min and produce oversized granules with D50 above 500 µm. The hydrophobic bis(trifluoromethyl)phenyl group in the intermediate-derived final API requires a wetting agent in the granulation fluid; sodium lauryl sulfate is added at 0.1–0.5% w/w of the granulation mass to prevent surface speckling, improve drug distribution, and maintain dissolution characteristics. After granulation, the wet mass is dried in a fluid-bed dryer with inlet air temperature 55–65 °C until residual moisture by loss-on-drying at 105 °C is 0.8–1.5%. Dry granules are milled through a 0.8 mm screen and the target particle size distribution is D10 30–60 µm, D50 150–250 µm, and D90 400–600 µm. Compression of milled granules is carried out on a rotary tablet press at 10–20 kN compression force, yielding tablet hardness of 70–110 N and friability below 0.3% when tested according to USP <1216>. Dissolution testing according to USP <711> is used to verify that the granulation path does not reduce the dissolution rate relative to direct compression; for poorly soluble NK1 antagonist products, a dissolution profile with Q not less than 75% at 45 min in 900 mL of surfactant-enriched medium is commonly used as the internal release criterion. Granulation is stopped immediately if the impeller power draw increases by more than 20% from baseline, because overwetting produces paste-like granulates that cannot be dried uniformly and generate high fine-particle fractions after milling. The granulation route is not used with the hydrochloride intermediate directly because the salt form dissolves in aqueous binder and undergoes local pH changes that can degrade the morpholine ether; conversion to the neutral final API is therefore a prerequisite for aqueous granulation.

When the Morpholine Intermediate Enters a Sterile Parenteral Supply Chain

Injectable presentations built from this chiral intermediate move through a fundamentally different control paradigm from oral solid dosage forms because the hydrochloride salt is not administered parenterally; the intermediate is used to construct the final morpholine-triazolinone core, which is then converted to a water-soluble phosphorylated prodrug for sterile lyophilization. The parenteral route imposes tighter residual solvent, related substance, and chiral purity constraints on the starting intermediate: dichloromethane is controlled to not more than 600 ppm, methanol to not more than 3000 ppm, tetrahydrofuran to not more than 720 ppm, and the total residual solvent profile is reported against ICH Q3C options. The phosphorylated prodrug solution is aseptically filtered through a 0.22 µm PVDF membrane and filled into Type I borosilicate glass vials at a target fill volume of 5–10 mL for a single intravenous dose. Lyophilization cycle development on a production freeze-dryer with shelf temperature uniformity of ± 1.0 °C and condenser capacity below −60 °C includes a freezing ramp from −40 °C to −50 °C, primary drying at −20 °C to −25 °C under 0.1–0.2 mbar chamber pressure, and secondary drying at 25–35 °C for 4–8 h until residual moisture by Karl Fischer titration is not more than 0.5%. The critical process conflict is pH: the phosphorylated prodrug retains acceptable solubility above pH 6.5, but hydrolytic degradation to the parent drug is accelerated above pH 8.0; formulation development therefore buffers the solution to pH 7.0–7.8 and avoids amine-based buffer additives that can catalyse phosphate ester cleavage. Published data for this specific pH-dependent degradation profile is limited; forced degradation studies under ICH Q1A conditions must be executed to define the stability envelope for each supplier’s intermediate and final prodrug. Sterility is verified according to USP <71>, bacterial endotoxin by USP <85> with a calculated limit typically not more than 0.5 EU/mg for intravenous NK1 antagonist prodrugs, and particulate matter by USP <788> with not more than 6000 particles per container at ≥ 10 µm and not more than 600 particles per container at ≥ 25 µm. The lyophilized plug must reconstitute in 0.9% sodium chloride injection within 2 min with gentle swirling; cake collapse, meltback, or visible aggregates are cause for batch rejection. Because the injectable presentation is a prodrug, the final drug product retains the morpholine stereocentres generated by the chiral intermediate, and any inversion at C2 or C3 before phosphorylation produces a diastereomeric prodrug that cannot be removed by standard reversed-phase HPLC and therefore must be controlled at the intermediate release step with chiral HPLC using amylose-based columns and n-hexane/ethanol mobile phases.

For patient populations that cannot swallow monolithic solid dosage forms, the final API prepared from this intermediate is processed into granules or powder for oral suspension filled into unit-dose sachets. The formulation approach differs from compressed tablets because the powder must disperse rapidly in water while maintaining the stereochemical integrity of the morpholine-derived drug substance during storage. A typical sachet formulation contains the micronized final API at 10–20% w/w, sucrose or mannitol as a water-soluble carrier, xanthan gum or hydroxyethyl cellulose as a suspending agent at 0.2–0.8% w/w, and citric acid/sodium citrate buffer to maintain the reconstituted pH between 4.0 and 6.0. The dry blend is prepared by geometric dilution in a low-shear tumble blender at 10–20 rpm for 20–40 min, then filled into aluminium foil sachets with a water vapour transmission rate not more than 0.1 g/m²/day at 38 °C/90% RH. Loss-on-drying of the final sachet contents is controlled to not more than 1.0%, because moisture ingress above 1.5% causes the micronized drug particles to aggregate and reduces the uniformity of the reconstituted suspension. Before release, the sachet contents are reconstituted in 20–30 mL of water and assessed for disperseibility; a screen test with a 250 µm sieve is used to confirm that not more than 2% of the labeled dose remains as non-dispersible agglomerates. In pediatric clinical supplies, the granule-filled sachet is dose-adjusted by body surface area, and content uniformity is assessed using USP <905> on single-dose units. This application is only feasible after the intermediate has been converted to the neutral final API because the hydrochloride salt imparts a bitter taste and the chloride counterion can increase hygroscopicity enough to destabilize the powder during storage. The oral suspension route is also used for nasogastric administration in oncology patients; the reconstituted suspension must pass through an 8 Fr feeding tube without clogging, which imposes a maximum particle size after reconstitution of 500 µm and a viscosity below 50 mPa·s at 25 °C as measured by a rotational viscometer.

Chiral HPLC Method Transfer for the Chloride Salt and Its Downstream Solid and Parenteral Forms

Across the tablet, capsule, granule, and injectable applications, the single most transferable analytical risk is the stereochemical integrity of the morpholine C2 and C3 positions. Chiral HPLC method transfer from the intermediate release laboratory to final dosage form quality control requires a column classification change only when the intermediate is derivatized or deprotected; for the isolated hydrochloride salt and the final API, an amylose-based chiral stationary phase with a normal-phase mobile phase of n-hexane, ethanol, and trifluoroacetic acid provides baseline resolution of the (2R,3S) and (2S,3R) diastereomers. System suitability is established with a resolution of not less than 2.0 between the critical diastereomer pair, a tailing factor not more than 2.0 according to USP <621>, and a signal-to-noise ratio of not less than 10 for the limit of quantification. Quantitation limits are typically set at 0.05% or below for the unwanted diastereomer in both the intermediate and the final drug substance, because the diastereomeric impurity can persist through N-alkylation, phosphorylation, and lyophilization and cannot be removed by recrystallization once the final prodrug is formed. For solid oral dosage forms, chiral identity testing is performed on compressed tablets and filled capsules by extraction of the API and re-injection into the same chiral HPLC method; sample preparation must avoid acid or base hydrolysis of the morpholine ether, and extraction recovery is validated across the range 80–120% with relative standard deviation not more than 5.0% at the limit of quantification. For parenteral presentations, chiral HPLC with evaporative light scattering or charged aerosol detection is used when the prodrug lacks a strong chromophore; the method is validated for linearity from 0.05% to 1.0% relative area, and the limit of detection is typically below 0.02%. The analytical transfer exercise is complete when the receiving laboratory generates a three-batch equivalence report comparing retention time, resolution, and relative response factor across intermediate, final API, and finished dosage form matrices; this report is retained as part of the quality unit’s method verification package under ICH Q2(R2) and ICH Q7 change control. Because the hydrochloride salt is the starting point for downstream manufacturing, any supplier of this intermediate must provide a certificate of analysis that includes specific rotation, chiral HPLC purity, residual solvents, loss on drying, and residue on ignition; the certificate is reviewed against the receiving laboratory’s release data before the lot is accepted for tablet, capsule, granule, or injectable production.